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Background: Autogenous arteriovenous fistula (AVF) has proven to be the optimal vascular access for the majority of
hemodialysis patients due to its durability and low complication rates. The purpose of this study is to determine the value
of intraoperative blood flow measurement with respect to AVF short-term outcome.
Methods: A prospective cohort study enrolled patients undergoing first time AVF creation surgery for hemodialysis from
November 2001 to April 2007. Intraoperative blood flowmeasurements were collected using transit time flowmeter, and
primary and secondary patency rates of AVF were examined. Other variables including age, sex, the presence of diabetes,
hypertension, or cerebrovascular disease, current smoking, systolic and diastolic blood pressure, heart rate, serum
calcium-phosphate product, and triglyceride and cholesterol level were analyzed.
Results:Autogenous radiocephalic AVFs (n 109) in 109 patients were constructed and followed up for an average of 21
months. Among these, 54% of patients were 60 years or older, 51% were male, and 56% were diabetics. One-year primary
and secondary patency rates for the high-flow group (>200 mL/min) were 69% and 94%, respectively. One-year primary
and secondary patency rates for the low-flow group (<200 mL/min) was 52% and 80%, respectively. Using hazard
analysis, intraoperative blood flow was the most important determinant of primary and secondary patency, in addition to
the presence of diabetes.
Conclusion: Intraoperative blood flow measurement is a predictor of the primary and secondary patency of autogenous
radiocephalic AVFs. Awareness of the significant correlation between intraoperative AVF blood flow and the short-term
outcome would enhance the surgical efficiency and maximize the usefulness of autogenous AVF. (J Vasc Surg 2008;48:
167-72.)There is extensive medical evidence supporting the use
of autogenous arteriovenous fistula (AVF) as the optimal
vascular access for the majority of hemodialysis patients.
The National Kidney Foundation’s Dialysis Outcomes
Quality Initiative (K/DOQI) developed renal care guide-
lines, including clinical practice recommendations and out-
come goals for vascular access. The K/DOQI Guidelines
2006 updates have highlighted their recommendations on
increasing the AVF prevalence rate greater than 65% of
patients.1 As the guidelines advise, autogenous fistulas
have the lowest rate of thrombosis, require the fewest
interventions, and provide long survival of access.2,3
Furthermore, the cost of autogenous AVF creation and
maintenance are the lowest.
However, failure of autogenous AVF to mature has
been described as a major limitation of their use and the
current study demonstrated that approximately 17% of
autogenous accesses failed within the first 3 months.3 De-
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emerges as an important issue, which might affect the
decision of surgical modality. Although the AVF blood
flow has been identified as a reliable indicator of short-term
thrombosis and failure risk,4,5 whether the initial blood
flow measured during AVF creation is predictive of the
short-term patency is only sporadically reported.6,7 We
began to measure the blood flow of AVFs during their
creation in 2001 and have since hypothesized that the
intraoperative AVF blood flow is an important predictor of
the surgical outcome.
METHODS
From November 2001 to April 2007, a total of 627
arteriovenous access procedures were performed by one
surgeon in a single institution, including 109 primary au-
togenous radiocephalic AVF, 93 primary and secondary
autogenous brachiocephalic AVF, 35 secondary brachio-
basilic transposition AVF, and 390 prosthetic graft implan-
tations. This cohort study enrolled 109 patients who re-
ceived primary autogenous radiocephalic AVF creation.
Informed consent was obtained before the time of surgery.
The inclusion criteria were new hemodialysis patients re-
ceiving first time AVF surgery and willing to complete the
follow-up.
One surgeon performed all the operations and used the
same technique. The operative procedure involved creation
of an anastomosis between the cephalic vein and radial
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sisted of careful inspection and palpation of the superficial
veins over the forearm and identification of a palpable radial
pulse with normal Allen’s test. The decision to perform
autogenous fistula creation or prosthetic graft implantation
depended on the actual vascular conditions identified dur-
ing surgery. A 2 to 3 cm incision was created, and the
cephalic vein was isolated, divided, and hydro-dilated. A 3F
Fogarty catheter was used to probe the cephalic vein to
ensure the continuity if discernible resistance felt in hydro-
dilatation of the cephalic vein. A venous diameter less than
2.5 mm or without arm continuity and an arterial diameter
less than 1.5mmor without brisk flow through arteriotomy
were considered not adequate for anastomosis. The end of
vein to the side of artery anastomosis was constructed using
7-0 polypropylene (Ethicon, Inc, Somerville, NJ) in a
continuous running suture line. Intraoperative blood flow
measurement was taken 10 minutes after completion of the
vascular anastomosis. A handheld 3 mm or 4 mm transit
time flowprobe, (Transonic HT107, Transonic System,
Inc, Ithaca, NY),8,9 was placed to encircle the cephalic vein,
about 5-10 mm behind the anastomosis according to the
limited room of incision, for direct measurement of AVF
blood flow. Measurements were repeated until consistent
flow data was obtained. The wound was then closed in a
single layer.
AVFs were allowed to be used after 8 to 12 weeks of
maturation time, and the follow-ups were completed until
the AVFwas no longer usable, the patient died, or the study
ended in May 2007. Primary patency was defined as the
time between AVF surgery and the first reintervention,
including angioplasty, surgical revision, or thrombectomy,
to restore or maintain patency. Secondary patency was
defined as the time between AVF surgery and permanent
failure of the AVF. The criteria requiring a reintervention
included high-pitched or systolic bruit on auscultation,
inability to attain the optimal dialysis flow of 250 mL/min,
increased dialysis venous pressure150 mmHg or a 30 to
50 mm Hg rise above the baseline value, the presence of
recirculation, and decline of AVF blood flow during sur-
veillance or any symptoms related to AVF such as pain, limb
swelling, or hand ischemia.10 AVF blood flow surveillance
was performed every 2months using an ultrasound dilution
technique, (HD01 Plus monitor, Transonic System, Inc,
Ithaca, NY)11 during hemodialysis. The decline of flow is
determined while the autogenous AVF flow 400 mL/
min and the graft flow 600 mL/min in our institution.
Operative data were collected at the time of surgery on
standardized data forms. Variables examined included in-
traoperative AVF blood flow, systolic blood pressure
(SBP), diastolic blood pressure (DBP), and heart rate
(HR). The following demographic characteristics were re-
corded: age, sex, the presence of diabetes mellitus (DM),
hypertension (HTN), cerebrovascular disease (CVD), cur-
rent smoking, plasma calcium-phosphate product level, and
triglyceride level and cholesterol level. This study was ap-
proved by the Institutional Review Board of our institu-
tion.Numerical variables were presented as the mean  SD
and discrete variables by percentages. The groups were
compared with the t test. The Kaplan-Meier method was
used to estimate the primary and secondary patency of
AVF. A case was censored when the patient died or the
study ended but no event occurred. To examine the rela-
tionship between intraoperative blood flow and AVF pa-
tency, patients were classified as high-flow (AVF blood flow
200 mL/min) and low-flow (AVF blood flow 200
mL/min) group. The cut-point of 200mL/min was estab-
lished after preliminary review of the data with an aim of
achieving sufficient numbers of patients in each group for
statistical analysis. In addition, 200 mL/min was the me-
dian value among our study sample (mean 213). Univar-
iate Cox proportional hazards regression analysis was used
to estimate the risk of reintervention (primary patency) or
failure (secondary patency), which is expressed as a hazard
ratio with a 95% confidence interval (CI). Significant vari-
ables (P  .2) were further evaluated in a multivariate Cox
model to identify which factor predicted the reintervention
and failure. P  .05 is considered statistically significant.
The analyses were performed using SPSS version 15.0
(SPSS, Chicago, Ill).
RESULTS
Patients (n  109) were followed up an average of 21
months (range, 1-67months; median, 18months). During
follow-ups, seven patients (6%) died, and 50 patients (46%)
had at least one fistula-related event such as temporary
access dysfunction or permanent AVF failure.
Demographic variables, surgical characteristics, and co-
morbid conditions are presented in Table I. The mean age
of patients was 60.17 14.1 years and 54% were older than
60 years. Among these, 51% of patients were male, 56% had
DM, 72% had HTN, and 12% had the history of CVD.
Besides, 19% of patients were current smokers. To facilitate
data analysis, we divided the patients into two groups
according to their calcium-phosphate product level.
K/DOQI clinical practice guidelines for bone metabolism
and disease in chronic kidney disease recommend that the
level should be maintained 55 mg2/dL2. As a result, 25%
of patients had levels over 55 mg2/dL2, and the mean level
was 48.7  20.4 mg2/dL2. Meanwhile, 48% of patients
had triglyceride level over 150 mg/dL, and 25% had cho-
lesterol level over 220 mg/dL (Table I).
The association between blood flow, demographic vari-
ables, and comorbid conditions are presented in Table I.
The mean blood flow in the low-flow group was 142.3 
34.8 mL/min and in high-flow group, 281.9  85.3
mL/min (P  .001). No demographic characteristics or
comorbid conditions were significantly different between
the two groups (Table I).
Autogenous AVFs with high flow (200 mL/min)
displayed superior primary and secondary patency rates
thanAVFswith low flow (200mL/min), as shown in Fig 1.
The one-year primary and secondary patency rates for the
high-flow group were 69% (31% reintervention) and 94%
(6% failure), significantly better compared with 52% (48%
f there
used.
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group (P-values .042 and .02, respectively). The patency
rates appeared to be steady after 2 years of survival (Fig 1).
Most AVF failures were due to thrombosis, inadequate
flow, and multiple venous stenoses.
During follow-up, eight patients (15%) in the low-flow
group and two patients (4%) in the high-flow group devel-
oped early failure within 3 months. Twenty-nine patients
(54%) in the low-flow group and 21 patients (38%) in the
high-flow group required reinterventions. Fistulogram re-
vealed 23 venous, 2 arterial and 4 combined lesions in the
low-flow group, and 18 venous, 1 arterial, and 2 combined
lesions in the high-flow group. The venous lesions were all
far behind the anastomosis and were likely the result of
previous venipuncture. The arterial lesions were due to
small and non-growing artery after AVF reconstruction.
Combined arterial and venous lesions were located close to
the AV anastomosis, so improper surgical technique such as
vascular clamping or manipulation may be attributed. Fur-
thermore, 21 AVFs of 29 patients (72%) in the low-flow
group were salvaged by reintervention and 19 AVFs of 21
patients (90%) in the high-flow group were salvaged.
The univariate Cox proportional hazards analysis to assess
risk for reintervention or failure is presented in Table II. For
each variable, a hazard ratio with a 95% CI was deter-
mined. The risk of reintervention (primary patency) or
failure (secondary patency) for the reference group listed in
parentheses was defined as equal to 1.0. Accordingly, in the
low-flow group, the hazard for reintervention was 1.87
Table 1. Demographic characteristics, surgical variables, a
Variable
Total pa
(n  1
Demographic characteristics
Age (y) 60.17 
Gender
Male 56 (5
Female 53 (4
SBP (mm Hg) 133.63 
DBP (mm Hg) 74.84 
HR 83.5 
Calcium-phosphate product level (mg2/dL2) 48.65 
Calcium-phosphate product level 55 22 (2
Triglyceride level (mg/dL) 161.9 
Triglyceride level 150 45 (4
Cholesterol level (mg/dL) 195.3 
Cholesterol level 220 23 (2
Surgical characteristics
AVF flow (mL/min) 212.73 
Comorbid conditions
DM 61 (5
HTN 78 (7
CVD 13 (1
Current smoker 21 (1
SBP, Systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate
Continuous variable are presented as the mean  SD and discrete variables
For continuous variables such as age and SBP, t tests were used to examine i
for categorical variables like gender and comorbid conditions, 2 tests weretimes higher than in the high-flow group. In the diabeticgroup, the hazard was 1.71 times higher than the nondia-
betic group. In addition, in the low-flow group, the hazard
for failure was 3.33 times higher than in the high-flow
group. The hazard for failure in the diabetic group was four
times than that of the nondiabetic group. No other demo-
graphic variables or comorbid conditions were significantly
associated with reintervention or failure.
The variables identified in the univariate analysis with a
P .20 were entered into the multivariate analysis that best
predicted the primary and secondary patency. Only those
variables that were significant are listed in Table III. Blood
flow and presence of diabetes emerged as the important
determinants for primary and secondary patency. Older age
was also associated with primary patency. The patients were
divided in four groups according to the presence of diabetes
and flow rate (Fig 2). The one-year primary and secondary
patency rates were only 47% and 70%, respectively, in the
patient group with diabetes and low flow, representing the
worst outcome in the patients receiving AVF surgery.
DISCUSSION
In this cohort study of patients undergoing primary
autogenous radiocephalic AVF creation, predictors for fis-
tula dysfunction and failure including preoperative charac-
teristics and intraoperative blood flow were examined.
Consequently, intraoperative blood flow correlated with
AVF outcome. With transit time ultrasonography technol-
ogy, the flowmeter measures flow volume directly without
any need for additional calculation related to cross-
omorbid conditions in AVF patient groups
High blood flow
(200 mL/
min) (n  55)
Low blood flow
(200 mL/
min) (n  54) P value
60.24  12.5 60.09  15.7 .99
32 (58%) 24 (44%) .154
23 (41%) 30 (55%)
9 134.16  24.4 133.09  26.2 .826
75.13  12.6 73.56  14.1 .824
85.0  10.9 82.19  12.1 .284
 46.03  15.2 51.39  24.6 .225
10 (22%) 12 (28%) .538
.1 153.1  90.1 172.4  132.1 .420
24 (47%) 21 (48%) .863
190.6  94.7 201.0  71.7 .546
9 (17%) 14 (33%) .081
281.9  85.3 142.3  34.8 .001
31 (56%) 30 (55%) .932
42 (76%) 36 (66%) .262
8 (14%) 5 (9%) .395
14 (25%) 7 (13%) .098
diabetes mellitus; HTN, hypertension; CVD, cerebrovascular disease.
rcent.
was differences between groups with high blood flow and low blood flow;nd c
tients
09)
14.1
1%)
8%)
25.1
13.3
11.6
 20.4
5%)
111
7%)
84.8
4%)
95.7
6%)
1%)
2%)
9%)
; DM,
by pesectional area, so the results are immediately available,
JOURNAL OF VASCULAR SURGERY
July 2008170 Lin et aleasily interpretable, and accurate.6-9 Transit time ultra-
sonography is diameter independent and less affected by
flow profile than is conventional duplex ultrasonogra-
phy. Conventional duplex ultrasonography measures
point velocity and assumes laminar flow, which is not
present in AVFs.6,7 In addition, expert or trained per-
sonnel is required and more time is consumed to perform
Fig 1. A, Primary patency in high-flow (200 mL/min) and
low-flow (200 mL/min) AVFs. B, Secondary patency in high-
flow (200 mL/min) and low-flow (200 mL/min) AVFs.the duplex ultrasonography. We usually achieved con-stant flow value within 1 minute after applying the transit
time flowprobe.
In 1998, Johnson et al7 was the first to use intraoper-
ative transit time ultrasonography for blood flow measure-
ment in a large number of patients, including 227 autoge-
nous AVFs and 162 polytetrafluoroethylene (PTFE) grafts
and correlated the blood flow with outcome. Using 320
mL/min as a cut-off value, they found a relationship be-
tween flow rates and outcome. A high flow (320 mL/
min) in the AVF predicted a lesser need for reintervention
and a superior ultimate survival, independent of demo-
graphic variables such as the age, race, sex, and the presence
of diabetes. Moreover, they showed that, when the radio-
cephalic AVF flow was 170 mL/min, the predicted fail-
ure within 90 days approached 56%. In 2000, Won et al6
employed the same transit time ultrasonography for intra-
operative blood flow measurements of 50 radiocephalic
AVFs and concluded fistulas with flow160 mL/min had
a higher failure rate and no correlation between early
patency and parameters of diabetes, old age, gender, flow
rate of radial artery, and the size of cephalic vein. Our study
also indicates that the intraoperative blood flow is predic-
tive of early failure or the need of reintervention and the
cut-off blood flow value was 200 mL/min. From these
data, it would imply that following the evolution of vascular
surgery and care, the outcome of AVF is improving as more
comprehensive attention and efficient management are
provided to patients. After the surgery, patients will have
information about how to take care the fistula by perform-
ing hand exercises or vascular massage to improve the
maturation and receive close follow-up to assess the func-
tion of newly created AVF.
In a systematic review of 34 studies, primary patency
rates for autogenous AVFs was 72% at 6 months and 51% at
18 months, whereas secondary patency rates was 86% at 6
months and 77% at 18 months.3 Our results revealed a
secondary one-year patency rate of 94% for the high-flow
group and 80% for the low-flow group. We attribute the
increased AVF survival, compared with previous studies 3 to
the early detection and efficient correction of the lesions
discovered in the poor maturation and malfunctioning
AVFs. At our institution, access flow surveillance program
was practiced every 2months during hemodialysis, using an
ultrasound dilution technique. The presence of any recir-
culation or decline of access blood flow as the autogenous
AVF flow 400 mL/min and the graft flow 600 mL/
min are considered an indication for a fistulogram study.
Early reintervention with percutaneous angioplasty or sur-
gical revision effectively improves the AVF function and
reduces the rate of AVF thrombosis,12,13 thus, potentially
avoiding permanent failure of fistula. We believe that early
reintervention to prevent thrombosis of AVF will reduce
the need of temporary access catheters, and the associated
complications, avoid under dialysis and decrease the emer-
gency admissions.
In addition to intraoperative blood flow, the presence
of diabetes was the other important negative predictor of
AVF patency, independent of high or low flow. The pres-
iate an
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times in primary and secondary patency, respectively. Other
studies14 have confirmed diabetes as an important risk
factor for AVF failure, and the poor results might be
explained by increased arterial disease and impaired venous
endothelial function. Fig 2 indicates that the patients with
low-flow and diabetes possessed the worst patency rates,
and the patency in the low-flow nondiabetic group was
even better than in the high-flow but diabetic group. The
1-year primary and secondary patency rates in the low-flow
diabetes group were 47% and 70%, respectively, signifi-
cantly lower than in the other three groups (P  .001).
We examined the relationship of serum calcium phos-
phate product, triglyceride level, and cholesterol level with
the outcome of AVF. Though plasma calcium-phosphate
product level, triglyceride and cholesterol levels are consid-
ered risk factors for poor AVF outcome, we did not find an
association with AVF short-term outcome. Presumably, the
ongoing changes of these plasma levels during the long-
term hemodialysis may reflect their adverse effects on AVFs,
and elevated calcium phosphate product level and choles-
terol level will predispose the vessel towards calcification
and atherosclerosis. Besides, in determining blood flow
rates, AVF blood flow represents the cumulative effect of all
the parameters and cannot be simply explained by hemo-
dynamic variables such as systolic and diastolic pressure or
Table II. Cox proportional hazards analysis of univariate
or failure (secondary patency)
Pri
Risk factor Hazard ratio (
Age  60 (vs  60) 1.75 (0.98-
Female (vs male) 1.15 (0.66-2
Diabetes (vs nondiabetes) 1.71 (0.96-3
HTN (vs non-HTN) 1.07 (0.58-1
CVD (vs non-CVD) 1.00 (0.52-2
Smoking (vs nonsmoking) 0.96 (0.46-1
CPPL 55 mg2/dL2 (vs 55) 1.19 (0.61-2
TG 150 mg/dL (vs 150) 1.12 (0.61-2
Cholesterol 220 mg/dL (vs 220) 1.51 (0.77-2
SBP 1.00 (0.99-1
DBP 1.00 (0.98-1
HR 1.00 (0.98-.
AVF blood flow 200 mL/min (vs 200) 1.87 (1.06-
CL, Confidence interval; HTN, hypertension; CVD, cerebrovascular diseas
pressure; DBP, diastolic blood pressure; HR, heart rate.
*Variables with a P value .2 are in bold and were included in the multivar
Table III. Variables that best predict primary and seconda
Group Variable
Primary patency Flow 200 mL/min (vs 20
Diabetes (vs nondiabetes)
Age 60 y ( vs 60)
Secondary patency Flow 200 mL/min (vs 20
Diabetes (vs nondiabetes)heart rate. We attempted to analyze the effect of SBP, DBP,and HR, but ultimately found no correlation with AVF
patency (Table II).
Intraoperative blood flow measurement has become
routine in AVF surgery in our hospital and distinguished
this procedure as a flow-guided surgical technique. We
consider that high blood flow measurements during AVF
surgery denote the success of operation and imply optimal
short-term patency rates. Likewise, we have found radioce-
phalic fistulas with a flow rate200 mL/min are at risk for
early failure. Thus, when low flow is encountered during
operation, intraoperative fistulogram is performed to ex-
clude the technical problems such as AV anastomotic stric-
ture, and to identify poor artery or vein. If the angiogram
revealed no technical problem necessitating correction, the
AVF is preserved with careful postoperative surveillance for
early reintervention to improve the secondary patency. A
proximal arm cephalic or transposed basilic vein for new
autogenous AVF creation, or a prosthetic graft implanta-
tion at the same setting should only be considered for
diabetic patients with low flow rates (200 mL/min). A
flow of 200 mL/min is useful as a reference value in the
constructive process, rather than as an absolute value.
In conclusion, intraoperative blood flow is an impor-
tant predictor of the primary and secondary patency of
autogenous radiocephalic AVFs. By using the transit time
flowmeter, flow information can be obtained with ease,
of variable on risk for reintervention (primary patency)
patency Secondary patency
I) P value* Hazard ratio (95% CI) P value
) .059 1.41 (0.51-3.89) .505
.628 0.71 (0.26-1.91) .498
.066 4.01 (1.14-14.2) .031
.835 1.32 (0.42-4.13) .633
.997 1.86 (0.43-2.35) .336
.901 1.55 (0.50-4.82) .449
.610 1.06 (0.34-3.34) .915
.711 1.58 (0.55-4.56) .398
.232 1.81 (0.61,5.41) .287
.923 1.00 (0.98-1.01) .910
.984 1.02 (0.98-1.06) .338
.768 0.99 (0.95-1.04) .718
) .029 3.33 (1.07-10.4) .038
PL, calcium-phosphate product level; TG, triglyceride; SBP, systolic blood
alysis.
atency by multivariate analysis
Relative hazard (95% CI) P value
1.92 (1.10-3.34) .021
1.98 (1.12-3.52) .019
1.79 (1.01-3.16) .045
3.50 (1.12-10.87) .031
4.22 (1.19-14.9) .026effect
mary
95% C
3.11
.00)
.04)
.99)
.54)
.97)
.32)
.05)
.94)
.01)
.02)
03)
3.28
e; CPry p
0)
0)accuracy, and reliability. In the era of more autogenous
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awareness of the significant correlation between intraoper-
Fig 2. A, Primary patency rates according to the presence of
diabetes mellitus and blood flow. B, Secondary patency rates
according to the presence of diabetes mellitus and blood flow.ative AVF blood flow and the short-term outcome wouldcertainly enhance the surgical efficiency of these patients
and maximize the most opportunity of autogenous AVF.
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